12/17
07:32 am
beam
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
07:00 am
beam
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/11
07:17 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Cantor Fitzgerald to a "hold" rating.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Cantor Fitzgerald to a "hold" rating.
12/9
06:22 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
12/9
12:54 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
12/9
11:15 am
beam
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains [Yahoo! Finance]
Low
Report
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains [Yahoo! Finance]
12/9
09:56 am
beam
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up [Yahoo! Finance]
Low
Report
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up [Yahoo! Finance]
12/8
01:50 pm
beam
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting [Yahoo! Fi
Low
Report
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting [Yahoo! Fi
12/8
01:45 pm
beam
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
Low
Report
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
12/7
11:34 am
beam
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
Low
Report
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
12/7
11:30 am
beam
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Low
Report
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
12/6
07:00 am
beam
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
Medium
Report
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
12/5
12:49 pm
beam
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? [Yahoo! Finance]
12/4
07:00 am
beam
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
Medium
Report
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
11/12
04:12 pm
beam
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference [Yahoo! Finance]
11/12
04:01 pm
beam
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
Low
Report
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
11/7
02:28 pm
beam
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch [Seeking Alpha]
Low
Report
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch [Seeking Alpha]
11/7
08:36 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
11/7
06:28 am
beam
Beam Therapeutics upgraded to Outperform from Market Perform at Leerink [Yahoo! Finance]
Low
Report
Beam Therapeutics upgraded to Outperform from Market Perform at Leerink [Yahoo! Finance]
11/7
06:22 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
11/6
01:26 pm
beam
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Low
Report
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
11/6
11:05 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target lowered by analysts at Royal Bank of Canada from $27.00 to $24.00. They now have a "sector perform" rating on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target lowered by analysts at Royal Bank of Canada from $27.00 to $24.00. They now have a "sector perform" rating on the stock.
11/6
08:05 am
beam
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Medium
Report
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
11/6
07:32 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $39.00 price target on the stock, up previously from $27.00.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $39.00 price target on the stock, up previously from $27.00.
11/6
02:22 am
beam
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... [Yahoo! Finance]
High
Report
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... [Yahoo! Finance]